Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Oncology Reports
Erschienen in: Current Oncology Reports 5/2022

24.02.2022 | Cardio-oncology (JN Upshaw, Section Editor)

Statins for Cardiac and Vascular Protection During and After Cancer Therapy

verfasst von: Emily M. Heiston, W. Gregory Hundley

Erschienen in: Current Oncology Reports | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Although cancer treatments have increased overall survival rates, the cardiovascular consequences of cancer therapy place patients at an increased risk of adverse outcomes. This manuscript presents data accumulated to date regarding cardiovascular outcomes relating to the administration of 3-hydroxy-3-methylglutarylcoenzyme-A reductase inhibitor (or statin) therapy in individuals receiving potentially cardiotoxic cancer treatments.

Recent Findings

Retrospective observational studies in humans and randomized controlled trials in animals suggest that statins may reduce cancer-specific and all-cause mortality. Further, statins may attenuate cancer therapy-induced declines in left ventricular ejection fraction (LVEF) and increases in blood pressure.

Summary

Observational studies suggest a potential attenuation in LVEF decline in patients with cancer and primary or secondary indications to receive a statin for prevention of cardiovascular events. Large randomized clinical trials are warranted to understand the efficacy and potential impacts of statin class, dosage, and duration on cardiovascular outcomes in patients treated for cancer.
Literatur
1.
Meléndez GC, Sukpraphrute B, D’Agostino RB, Jordan JH, Klepin HD, Ellis L, et al. Frequency of left ventricular end-diastolic volume-mediated declines in ejection fraction in patients receiving potentially cardiotoxic cancer treatment. Am J Cardiol. 2017;119:1637–42.CrossRefPubMedPubMedCentral
2.
Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med. 1996;125:47–58.CrossRefPubMed
3.
Zhang S, Liu X, Bawa-Khalfe T, Lu L-S, Lyu YL, Liu LF, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18:1639–42.CrossRefPubMed
4.
Wiggins BS, Saseen JJ, Page RL, Reed BN, Sneed K, Kostis JB, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the american heart association. Circulation. 2016;134:e468–95.CrossRefPubMed
5.
Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res Am Heart Assoc. 2017;120:229–43.
6.
Manthravadi S, Shrestha A, Madhusudhana S. Impact of statin use on cancer recurrence and mortality in breast cancer: a systematic review and meta-analysis. Int J Cancer. 2016;139:1281–8.CrossRefPubMed
7.
Mei Z, Liang M, Li L, Zhang Y, Wang Q, Yang W. Effects of statins on cancer mortality and progression: a systematic review and meta-analysis of 95 cohorts including 1,111,407 individuals. Int J Cancer. 2017;140:1068–81.CrossRefPubMed
8.
9.
Warnecke B, Djoufack Djoumessi RL, Garza J, Mader M, Chaudhary S, Datta P. The effect of statins on overall survival and progression-free survival in veterans with prostate cancer: a retrospective single-center experience. J Clin Oncol. 2021;39:169–169.
10.
Ray KK, Seshasai SRK, Erqou S, Sever P, Jukema JW, Ford I, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65 229 participants. Arch Intern Med. 2010;170:1024–31.CrossRefPubMed
11.
Emilsson L, García-Albéniz X, Logan RW, Caniglia EC, Kalager M, Hernán MA. Examining bias in studies of statin treatment and survival in patients with cancer. JAMA Oncol. 2018;4:63–70.CrossRefPubMed
12.
Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. Circ Am Heart Assoc. 2019;140:e596–646.
13.
Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the european society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315–81.CrossRefPubMedPubMedCentral
14.
Nohria A, Prsic A, Liu P-Y, Okamoto R, Creager MA, Selwyn A, et al. Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis. 2009;205:517–21.CrossRefPubMed
15.
Gnad R, Kaina B, Fritz G. Rho GTPases are involved in the regulation of NF-kappaB by genotoxic stress. Exp Cell Res. 2001;264:244–9.CrossRefPubMed
16.
Strand LN, Young RL, Bertoni AG, Bluemke DA, Burke GL, Lima JA, et al. New statin use and left ventricular structure: estimating long-term associations in the Multi-Ethnic Study of Atherosclerosis (MESA). Pharmacoepidemiol Drug Saf. 2018;27:570–80.CrossRefPubMedPubMedCentral
17.
Gürgün C, Ildizli M, Yavuzgil O, Sin A, Apaydin A, Cinar C, et al. The effects of short term statin treatment on left ventricular function and inflammatory markers in patients with chronic heart failure. Int J Cardiol. 2008;123:102–7.CrossRefPubMed
18.
Förstermann U, Münzel T. Endothelial nitric oxide synthase in vascular disease. Circ Am Heart Assoc. 2006;113:1708–14.
19.
Massaro M, Zampolli A, Scoditti E, Carluccio MA, Storelli C, Distante A, et al. Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability. Cardiovasc Res. 2010;86:311–20.CrossRefPubMed
20.
Leenders GJ, Smeets MB, van den Boomen M, Berben M, Nabben M, van Strijp D, et al. Statins promote cardiac infarct healing by modulating endothelial barrier function revealed by contrast-enhanced magnetic resonance imaging. Arterioscler Thromb Vasc Biol. 2018;38:186–94.CrossRefPubMed
21.
22.
Godoy JC, Niesman IR, Busija AR, Kassan A, Schilling JM, Schwarz A, et al. Atorvastatin, but not pravastatin, inhibits cardiac Akt/mTOR signaling and disturbs mitochondrial ultrastructure in cardiac myocytes. FASEB J. 2019;33:1209–25.CrossRefPubMed
23.
24.
Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to statins and risk of common cancers: a series of nested case-control studies. BMC Cancer. 2011;11:409.CrossRefPubMedPubMedCentral
25.
Eaton M, Eklof J, Beal JR, Sahmoun AE. Statins and breast cancer in postmenopausal women without hormone therapy. Anticancer Res Int Inst Anticancer Res. 2009;29:5143–8.
26.
Bjerre LM, LeLorier J. Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med. 2001;110:716–23.CrossRefPubMed
27.
Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer riska meta-analysis. JAMA. 2006;295:74–80.CrossRefPubMed
28.
Lubet RA, Boring D, Steele VE, Ruppert JM, Juliana MM, Grubbs CJ. Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis. Cancer Prev Res Am Assoc Cancer Res. 2009;2:161–7.
29.
Ahern TP, Pedersen L, Tarp M, Cronin-Fenton DP, Garne JP, Silliman RA, et al. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst. 2011;103:1461–8.CrossRefPubMedPubMedCentral
30.
Kwon H, Pessin JE. Adipokines mediate inflammation and insulin resistance. Front Endocrinol (Lausanne). 2013;4:71.CrossRef
31.
Kochhar R, Khurana V, Bejjanki H, Caldito G, Fort C. Statins to reduce breast cancer risk: A case control study in U.S. female veterans. J Clin Oncol. 2005;23:514–514.
32.
Shannon J, Tewoderos S, Garzotto M, Beer TM, Derenick R, Palma A, et al. Statins and prostate cancer risk: a case-control study. Am J Epidemiol. 2005;162:318–25.CrossRefPubMed
33.
Poynter JN, Gruber SB, Higgins PDR, Almog R, Bonner JD, Rennert HS, et al. Statins and the risk of colorectal cancer. N Engl J Med. 2005;352:2184–92.CrossRefPubMed
34.
Yin L, He Z, Yi B, Xue L, Sun J. Simvastatin suppresses human breast cancer cell invasion by decreasing the expression of pituitary tumor-transforming gene 1. Front Pharmacol. 2020;11:574068.CrossRefPubMedPubMedCentral
35.
Wang G, Cao R, Wang Y, Qian G, Dan HC, Jiang W, et al. Simvastatin induces cell cycle arrest and inhibits proliferation of bladder cancer cells via PPARγ signalling pathway. Sci Rep. 2016;6:35783.CrossRefPubMedPubMedCentral
36.
Larsson O. HMG-CoA reductase inhibitors: role in normal and malignant cells. Crit Rev Oncol Hematol. 1996;22:197–212.CrossRefPubMed
37.
Mullen PJ, Yu R, Longo J, Archer MC, Penn LZ. The interplay between cell signalling and the mevalonate pathway in cancer. Nat Rev Cancer. 2016;16:718–31.CrossRefPubMed
38.
Borahay MA, Kilic GS, Yallampalli C, Snyder RR, Hankins GDV, Al-Hendy A, et al. Simvastatin potently induces calcium-dependent apoptosis of human leiomyoma cells. J Biol Chem. 2014;289:35075–86.CrossRefPubMedPubMedCentral
39.
Masoudkabir F, Sarrafzadegan N, Gotay C, Ignaszewski A, Krahn AD, Davis MK, et al. Cardiovascular disease and cancer: Evidence for shared disease pathways and pharmacologic prevention. Atherosclerosis. 2017;263:343–51.CrossRefPubMedPubMedCentral
40.
Spampanato C, De Maria S, Sarnataro M, Giordano E, Zanfardino M, Baiano S, et al. Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and down-regulation of BCL-2 gene expression. Int J Oncol. 2012;40:935–41.CrossRefPubMed
41.
Riad A, Bien S, Westermann D, Becher PM, Loya K, Landmesser U, et al. Pretreatment with statin attenuates the cardiotoxicity of Doxorubicin in mice. Cancer Res. 2009;69:695–9.CrossRefPubMed
42.
Yoshida M, Shiojima I, Ikeda H, Komuro I. Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA damage-ATM-p53-apoptosis pathway and attenuated by pitavastatin through the inhibition of Rac1 activity. J Mol Cell Cardiol. 2009;47:698–705.CrossRefPubMed
43.
Huelsenbeck J, Henninger C, Schad A, Lackner KJ, Kaina B, Fritz G. Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity. Cell Death Dis. 2011;2:e190.CrossRefPubMedPubMedCentral
44.
Henninger C, Huelsenbeck S, Wenzel P, Brand M, Huelsenbeck J, Schad A, et al. Chronic heart damage following doxorubicin treatment is alleviated by lovastatin. Pharmacol Res. 2015;91:47–56.CrossRefPubMed
45.
Sharma H, Pathan RA, Kumar V, Javed S, Bhandari U. Anti-apoptotic potential of rosuvastatin pretreatment in murine model of cardiomyopathy. Int J Cardiol. 2011;150:193–200.CrossRefPubMed
46.
Kim Y-H, Park S-M, Kim M, Kim SH, Lim S-Y, Ahn J-C, et al. Cardioprotective effects of rosuvastatin and carvedilol on delayed cardiotoxicity of doxorubicin in rats. Toxicol Mech Methods. 2012;22:488–98.CrossRefPubMed
47.
Cho D-H, Lim I-R, Kim J-H, Kim M-N, Kim Y-H, Park KH, et al. Protective effects of statin and angiotensin receptor blocker in a rat model of doxorubicin- and trastuzumab-induced cardiomyopathy. J Am Soc Echocardiogr. 2020;33:1253–63.CrossRefPubMed
48.
Seicean S, Seicean A, Plana JC, Budd GT, Marwick TH. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol. 2012;60:2384–90.CrossRefPubMed
49.
Chotenimitkhun R, D’Agostino R, Lawrence JA, Hamilton CA, Jordan JH, Vasu S, et al. Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function. Can J Cardiol. 2015;31:302–7.CrossRefPubMed
50.
Calvillo-Argüelles O, Abdel-Qadir H, Michalowska M, Billia F, Suntheralingam S, Amir E, et al. Cardioprotective effect of statins in patients with her2-positive breast cancer receiving trastuzumab therapy. Can J Cardiol. 2019;35:153–9.CrossRefPubMed
51.
Lang JK, Karthikeyan B, Quiñones-Lombraña A, Blair RH, Early AP, Levine EG, et al. CBR3 V244M is associated with LVEF reduction in breast cancer patients treated with doxorubicin. Cardiooncology. 2021;7:17.PubMedPubMedCentral
52.
Boulet J, Peña J, Hulten EA, Neilan TG, Dragomir A, Freeman C, et al. Statin use and risk of vascular events among cancer patients after radiotherapy to the thorax, head, and neck. J Am Heart Assoc. 2019;8:e005996.CrossRefPubMedPubMedCentral
53.
Kim J, Nishimura Y, Kewcharoen J, Yess J. Statin use can attenuate the decline in left ventricular ejection fraction and the incidence of cardiomyopathy in cardiotoxic chemotherapy recipients: a systematic review and meta-analysis. J Clin Med. 2021;10:3731.CrossRefPubMedPubMedCentral
54.
Abdel-Qadir H, Bobrowski D, Zhou L, Austin PC, Calvillo-Argüelles O, Amir E, et al. Statin exposure and risk of heart failure after anthracycline- or trastuzumab-based chemotherapy for early breast cancer: a propensity score-matched cohort study. J Am Heart Assoc. 2021;10:e018393.CrossRefPubMedPubMedCentral
55.
Feng J-L, Qin X. Does adherence to lipid-lowering medications improve cancer survival? A nationwide study of breast and colorectal cancer, and melanoma. Br J Clin Pharmacol. 2021;87:1847–58.CrossRefPubMed
56.
Cardwell CR, Mc Menamin Ú, Hughes CM, Murray LJ. Statin use and survival from lung cancer: a population-based cohort study. Cancer Epidemiol Biomarkers Prev. 2015;24:833–41.CrossRefPubMed
57.
Acar Z, Kale A, Turgut M, Demircan S, Durna K, Demir S, et al. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2011;58:988–9.CrossRefPubMed
58.
Nabati M, Janbabai G, Esmailian J, Yazdani J. effect of rosuvastatin in preventing chemotherapy-induced cardiotoxicity in women with breast cancer: a randomized, single-blind, placebo-controlled trial. J Cardiovasc Pharmacol Ther. SAGE Publications Inc. 2019;24:233–41.
59.
Murtola TJ, Syvälä H, Tolonen T, Helminen M, Riikonen J, Koskimäki J, et al. Atorvastatin versus placebo for prostate cancer before radical prostatectomy-a randomized, double-blind, placebo-controlled. Clinical Trial Eur Urol. 2018;74:697–701.CrossRefPubMed
60.
Raittinen PVH, Syvälä H, Tammela TLJ, Häkkinen MR, Ilmonen P, Auriola S, et al. Atorvastatin induces adrenal androgen downshift in men with prostate cancer: a post hoc analysis of a pilot adaptive randomised clinical trial. EBioMedicine. 2021;68:103432.CrossRefPubMedPubMedCentral
61.
62.
63.
64.
65.
Khanna A, Pequeno P, Gupta S, Thavendiranathan P, Lee DS, Abdel-Qadir H, et al. Increased risk of all cardiovascular disease subtypes among childhood cancer survivors: population-based matched cohort study. circulation. 2019;140:1041–3.CrossRefPubMed
66.
Marlatt KL, Steinberger J, Rudser KD, Dengel DR, Sadak KT, Lee JL, et al. The Effect of atorvastatin on vascular function and structure in young adult survivors of childhood cancer: a randomized, placebo-controlled pilot clinical trial. J Adolesc Young Adult Oncol. 2019;8:442–50.CrossRefPubMedPubMedCentral
67.
Tan X-L, E J-Y, Lin Y, Rebbeck TR, Lu S-E, Shang M, et al. Individual and joint effects of metformin and statins on mortality among patients with high-risk prostate cancer. Cancer Med 9:2379–89.
Metadaten
Titel
Statins for Cardiac and Vascular Protection During and After Cancer Therapy
verfasst von
Emily M. Heiston
W. Gregory Hundley
Publikationsdatum
24.02.2022
Verlag
Springer US
Erschienen in
Current Oncology Reports / Ausgabe 5/2022
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-022-01212-4

Weitere Artikel der Ausgabe 5/2022

Current Oncology Reports 5/2022 Zur Ausgabe

Genitourinary Cancers (DP Petrylak and JW Kim, Section Editors)

Management of Upper Tract Urothelial Carcinoma

Palliative Medicine (A Jatoi, Section Editor)

The Value Proposition of Observation Medicine in Managing Acute Oncologic Pain

Immuno-oncology (RM Bukowski and JH Finke, Section Editors)

Fatty Acid Metabolism and Cancer Immunotherapy

Leukemia (A Aguayo, Section Editor)

Large Granular Lymphocytic Leukemia: Current State of Diagnosis, Pathogenesis and Treatment

Genitourinary Cancers (DP Petrylak and JW Kim, Section Editors)

Clinicopathological Review of Micropapillary Urothelial Carcinoma

Cardio-oncology (JN Upshaw, Section Editor)

Radiation-Induced Cardiovascular Disease: Mechanisms, Prevention, and Treatment

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise